Flecainide

Flecainide
Clinical data
Pronunciation	/flɛˈkeɪnaɪd/ fleh-KAY-nyde
Trade names	Tambocor, others
AHFS/Drugs.com	Monograph
MedlinePlus	a608040
Drug class	Ic antiarrhythmic
ATC code	C01BC04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	95%
Protein binding	40%
Metabolism	CYP2D6 (limited)
Elimination half-life	20 hours (range 12–27 hours)
Excretion	Kidney
Identifiers
	IUPAC name (RS)-N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide;
CAS Number	54143-55-4 ;
PubChem CID	3356;
IUPHAR/BPS	2560;
DrugBank	DB01195 ;
ChemSpider	3239 ;
UNII	K94FTS1806;
KEGG	D07962 ;
ChEBI	CHEBI:75984 ;
ChEMBL	ChEMBL652 ;
CompTox Dashboard (EPA)	DTXSID8023054 ;
ECHA InfoCard	100.211.334
Chemical and physical data
Formula	C17H20F6N2O3
Molar mass	414.348 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES FC(F)(F)COc2cc(C(=O)NCC1NCCCC1)c(OCC(F)(F)F)cc2;
	InChI InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26) ; Key:DJBNUMBKLMJRSA-UHFFFAOYSA-N ;
	(what is this?) (verify)

Flecainide is a medication used to prevent and treat abnormally fast heart rates.^[1] This includes ventricular and supraventricular tachycardias.^[1] Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments.^[1] Its use does not decrease a person's risk of death.^[1] It is taken by mouth or injection into a vein.^[1]^[2]

Common side effects include dizziness, problems seeing, shortness of breath, chest pain, and tiredness.^[1] Serious side effects may include cardiac arrest, arrhythmias, and heart failure.^[1] It may be used in pregnancy, but has not been well studied in this population.^[2]^[3] Use is not recommended in those with structural heart disease or ischemic heart disease.^[1] Flecainide is a class Ic antiarrhythmic agent.^[1] It works by decreasing the entry of sodium in heart cells, causing prolongation of the cardiac action potential.^[1]

Flecainide was approved for medical use in the United States in 1985.^[1] It is available as a generic medication.^[2] In 2021, it was the 205th most commonly prescribed medication in the United States, with more than 2 million prescriptions.^[4]^[5]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l "Flecainide Acetate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 7 April 2019.
^ ^a ^b ^c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 103. ISBN 9780857113382.
^ "Flecainide (Tambocor) Use During Pregnancy". Drugs.com. Retrieved 7 April 2019.
^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^ "Flecainide - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

[AHFS2019-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l "Flecainide Acetate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 7 April 2019.

[BNF76-2] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 103. ISBN 9780857113382.

[3] "Flecainide (Tambocor) Use During Pregnancy". Drugs.com. Retrieved 7 April 2019.

[4] "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.

[5] "Flecainide - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

[1]

[2]

[3]

[4]

[5]